Artificial Intelligence in Molecular Imaging: Predicting Parkinson's Risk in REM Sleep Behavior Disorder

Launched by INSEL GRUPPE AG, UNIVERSITY HOSPITAL BERN · Oct 4, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how artificial intelligence can help identify people at risk of developing Parkinson's disease and other related conditions, like dementia and multiple system atrophy. Researchers want to better understand the progression of a condition called REM Sleep Behavior Disorder (RBD), where individuals act out their dreams, and find ways to predict who might be at higher risk for these serious diseases in the future. Participants in the study will undergo clinical evaluations and two imaging tests to gather important information.

To be eligible for this trial, participants must have a confirmed diagnosis of RBD by a specialist and must provide written consent to take part. However, those with a known diagnosis of Parkinson's disease or other similar disorders, obvious signs of movement problems, or certain sleep disorders may not qualify. If you decide to join, you will be contributing to important research that could lead to better ways to predict these conditions and improve patient care.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Confirmed clinical iRBD diagnosis by movement disorder specialists according to the International Classification of Sleep Disorders
• • 2. Written informed consent
• Exclusion Criteria:
• • 1. Known diagnosis of PD or other neurodegenerative disorder
• • 2. Unequivocal signs of parkinsonism on examination
• • 3. Narcolepsy or other known causes of RBD
• • 4. Moderate to severe obstructive sleep apnea
• • 5. Abnormal neurological or MRI examination